RVX has closed at or above $3CAD only once since 6/5/13 after the runup to the Assure trial result announcement

The stock then languished in the depths and  closed at $3CAD on 04/14/15 when Hepalink partnered with RVX to fund the Betonmace trial. RVX then spun off Zenith - created the royalty preferred shares - and diverted a goodly portion of their intellectual property

so we now have RVX with a street value of $226MMCAD and Zenith with a $675MMCAD valuation as floated by DM a total of $901MMCAD or ~ $7CAD per share for the total package based on full dilution of ~125MMshares had Newco not been formed

I realize it is an oversimplification of the valuation - I am still waiting for the other 1 or 2 analyst reports to help us all out - what's up with that?

Perhaps the future committment to the Royalty stream for RVX has confused and kept many potential investors and partners from partaking in this endeavor

RVX-208 has pioneered this new concept and unlocked a potential cure to many pervasive deseases -

The clinical data is extremely promising - IMHO the sky is the limit if RVX is first to market

Chicagoest